You just read:

Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 Investigational Gene Therapy For Hemophilia A

News provided by

Sangamo Therapeutics, Inc.

Aug 25, 2017, 08:00 ET